NCT01527786

Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine

A Pilot Study of Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: BC Women's Hospital & Health Centre · Academic / Other
• Sex: Female
• Age: 19 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Postpartum depressed women suffer from functional impairment in their mood, thoughts, cognition and physical well being leading to poor motivation, bonding difficulties, decreased productivity, conflict and neglect. Moderate/ severe depression responds best to a combination of antidepressants and counseling. This study will estimate the proportion of women who return to functionality after treatment with Desvenlafaxine and examine the differential impact of change in depression and anxiety symptoms on functionality over twelve weeks. Depression and anxiety symptoms will be monitored through six mood questionnaires; functional recovery will be monitored through a simple self-report questionnaire at each visit.

Detailed description

Women will be recruited through a tertiary level care program and advertisements in BC Children's \& Women's Hospital as well as St.Paul's Hospital, Vancouver, B.C., Canada. If deemed eligible for the study (meeting a diagnosis of postpartum depression with or without comorbid anxiety disorder) and the potential participant agrees to participate, consent will be signed. The participant will return on a bi-weekly basis for study visits, where mood and anxiety will be monitored, in addition to blood pressure and weight. Starting dose of Desvenlafaxine is 50mg, and this can be titrated to 100mg/per day if needed. Questionnaires will assess depression symptoms, anxiety symptoms, quality of life, panic disorder, obsessive-compulsive disorder and generalized anxiety disorder.

Conditions

• Depression

Interventions

Type	Name	Description
DRUG	Desvenlafaxine	50mg-100mg everyday for 12 weeks over 7 study visits

Timeline

• Start date: 2010-11-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2012-02-07
• Last updated: 2015-01-28

Locations

1 site across 1 country: Canada